Ginkgo Bioworks Holdings, Inc. Income Statement
DNA / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Ginkgo Bioworks Holdings, Inc. reported $170M in revenue and $313M in net loss for FY2025. Revenue has grown at a 21.0% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| SG&A Expense | $183.3M | $246.2M | $385.0M | $1.4B | $863.0M | $38.3M | $29.5M |
| R&D Expense | $243.8M | $424.1M | $580.6M | $1.1B | $1.1B | $159.8M | $96.3M |
| Operating Income | -$315.3M | -$559.8M | -$864.4M | -$2.2B | -$1.8B | -$137.0M | -$71.6M |
| Interest Expense | - | - | $93.0K | $106.0K | $2.4M | $2.4M | $2.4M |
| Income Tax | -$837.0K | -$479.0K | -$71.0K | -$15.0M | -$1.5M | $1.9M | $22.0K |
| Net Income | -$312.8M | -$547.0M | -$892.9M | -$2.1B | -$1.8B | -$126.6M | -$119.3M |
| EPS (Basic) | -$18.37 | -$50.15 | -$1.35 | -$0.10 | -$0.10 | -$0.10 | -$0.10 |
| EPS (Diluted) | -$18.37 | -$50.20 | -$1.39 | -$0.10 | -$0.10 | -$0.10 | -$0.10 |
| Shares Outstanding | 54.4M | 50.0M | 1.9B | 1.6B | 1.3B | 1.3B | 1.1B |
| Operating Margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | - | - |
| Profit Margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | - |